Prostate Cancer Treatment and Research
Peer reviewed
Scollr summary
What this paper is about
The addition of short-course enzalutamide to [177Lu]Lu-PSMA-617 did not meaningfully improve treatment outcomes of taxane and ARPI-exposed mCRPC patients in this trial.
Full abstract
Read the full abstract
ABSTRACT Background [ 177 Lu]Lu‐PSMA‐617 has been an approved treatment modality for metastatic castration‐resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, which may enhance the outcomes with [ 177 Lu]Lu‐PSMA‐617. This study aims to evaluate the efficacy and safety of short‐course enzalutamide priming with [ 177 Lu]Lu‐PSMA‐617 in mCRPC patients. Methods This investigator‐initiated, single‐arm phase 2 trial recruited men with mCRPC, having progressed on ≥one line of taxane and androgen‐receptor pathway inhibitors (ARPIs), and fit for [ 177 Lu]Lu‐PSMA‐617. Enzalutamide (160 mg/day) was administered orally for 7 days before and after [ 177 Lu]Lu‐PSMA‐617 (7.4 GBq/cycle, up to 6 cycles, at 6–8 week intervals). The primary end‐point was proportion of patients achieving ≥ 50% decline in prostate‐specific antigen (PSA50‐response rate, PSA50‐RR). A sample size of 20 patients was calculated using Simon's two‐stage design with at least 12/20 PSA50‐responses required for rejection of null hypothesis. Secondary end‐points included objective radiographic response rate (ORR), PSA progression‐free survival (PSA‐PFS), radiographic PFS (rPFS), overall survival (OS), and adverse events (AEs). Results Between May 2023 and January 2025, 20 mCRPC patients (median age 67 years) were enrolled. The PSA50‐RR was 40% (8/20, 95% CI: 19–64), thus the null hypothesis was not rejected. The ORR was 25% (5/20, 95% CI: 10–49). Over a median follow‐up of 24 months, median PSA‐PFS, rPFS, and OS were 4.0 months (95% CI: 3.0–7.5), 4.0 months (95% CI: 4.0–7.5), and 12.6 months (95% CI: 6.2–17.0), respectively. Grade 3 AEs were observed in four patients (20%, 95% CI: 6–44). Conclusion The addition of short‐course enzalutamide to [ 177 Lu]Lu‐PSMA‐617 did not meaningfully improve treatment outcomes of taxane and ARPI‐exposed mCRPC patients in this trial. Trial Registration Clinical Trials Registry‐India, CTRI/2023/05/053301. Registered 31 May 2023.
Direct answer
What can I do from this paper page?
Use this page to scan "[ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Prostate Cancer Treatment and Research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Aggarwal2026PSMA,
title = {[ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)},
author = {Piyush Aggarwal and Ashwani Sood and Swayamjeet Satapathy and Shikha Goyal and Komalpreet Kaur and Gaurav Prakash and Kannan Periasamy and Bhagwant Rai Mittal},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70253},
url = {https://doi.org/10.1002/pros.70253}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Prostate Cancer Treatment and Research papers?
Follow Prostate Cancer Treatment and Research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for [ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME). Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app